Floris Louis Van Delft

This inventor holds 32 USPTO granted patents and 30 published patent applications and 16 EPO patents, primarily in Bioconjugate Chemistry. Top assignees: Synaffix B.v., Synahix B.v.. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Floris Louis Van Delft. Retrieved from https://idiyas.com/inventor/floris-louis-van-delft

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 32 (Patent Applications = 30)

% Patents Active = 96.9

EPO Patents = 16 (Patent Applications = 52)

Average Co-Inventor Count = 3.8

ph-index = 6

Forward Citations = 321(Granted Patents)

Location History:

KZ Nijmegen, NL (2022)
Nijmegen, NL (2014 - 2024)

Company Filing History:

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

Bioconjugates

Sulfamide Linkers

Glycoprotein Modification

Antibody-Conjugates

Enediyne Conjugates

Fused Cyclooctyne Compounds

Therapeutic Index

Click Reactions

Glycosyltransferase

Trimming Enzymes

1,3-Dipole Compound

Cycloalkyne

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12642861 - Enediyne conjugates (2026-06-02),

2. 12440573 - Antibody-conjugates for targeting of tumours expressing PTK7 (2025-10-14),

3. 12397063 - Antibody-conjugates for targeting of tumours expressing Trop-2 (2025-08-26),

4. 12281135 - Synthesis of 6-azido-6-deoxy-2-n-acetyl-hexosamine-nucleoside diphosphate (2025-04-21),

5. 12194107 - Modified antibody, antibody-conjugate and process for the preparation thereof (2025-01-14),

6. 12180145 - Fused cyclooctyne compounds and their use in metal-free click reactions (2024-12-31),

7. 12084448 - Process for the cycloaddition of a (hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyne (2024-09-10),

8. 12049656 - Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from a β(1,4)-n-acetylgalactosaminyltransferase (2024-07-30),

9. 11957763 - Sulfamide linkers for use in bioconjugates (2024-04-16),

10. 11951175 - Bioconjugates containing sulfamide linkers for use in treatment (2024-04-09),

11. 11850286 - Sulfamide linker, conjugates thereof, and methods of preparation (2023-12-26),

12. 11713453 - Enzymes for trimming of glycoproteins (2023-08-01),

13. 11590239 - Antibody-conjugates with improved therapeutic index for targeting CD30 tumours and method for improving therapeutic index of antibody-conjugates (2023-02-28),

14. 11547763 - Enediyne conjugates (2023-01-10),

15. 11358921 - Fused cyclooctyne compounds and their use in metal-free click reactions (2022-06-14),

Title: Innovations by Floris Louis Van Delft

Introduction

Floris Louis Van Delft, an acclaimed inventor based in Nijmegen, Netherlands, has made significant contributions to the field of biotechnology through his numerous patents. With a total of 28 patents to his name, his work primarily focuses on the development of novel antibody-conjugates and advanced chemical compounds.

Latest Patents

One of his recent patents is for a modified antibody that incorporates a GlcNAc-S(A) substituent. This invention is significant for its application in antibody-conjugates where the N-acetylglucosamine can be optionally fucosylated. Additionally, he has developed fused cyclooctyne compounds, which are pivotal for bioorthogonal labeling and imaging applications, enhancing the capabilities in modifying target molecules.

Career Highlights

Throughout his career, Floris has worked with renowned companies like Synaffix B.V., where he has contributed to innovative projects that have potential implications in therapeutic development. His extensive portfolio showcases not only the inventions but also the methodologies behind creating such complex bioconjugates.

Collaborations

Floris has collaborated with talented professionals in his field such as Maria Antonia Wijdeven and Sander Sebastiaan Van Berkel. These partnerships have been instrumental in pushing the boundaries of research and application in biotechnology, bringing forth impactful inventions that stand out in the scientific community.

Conclusion

Floris Louis Van Delft’s innovative spirit and dedication to advancing biotechnological research are evident through his extensive patent portfolio. His inventions and collaborations are shaping the future of antibody-conjugates and chemical compounds, offering promising avenues in medical applications and beyond.

Profile summary based on public USPTO records.